Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | serine peptidase, clan SC, family S9A-like protein, putative | 0.0052 | 0.2275 | 0.3126 |
Echinococcus granulosus | histone acetyltransferase KAT2B | 0.0143 | 0.814 | 0.814 |
Giardia lamblia | Histone acetyltransferase GCN5 | 0.004 | 0.1515 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.013 | 0.7278 | 0.8264 |
Plasmodium falciparum | histone acetyltransferase GCN5 | 0.004 | 0.1515 | 1 |
Trypanosoma cruzi | prolyl endopeptidase | 0.013 | 0.7278 | 1 |
Mycobacterium ulcerans | protease II (oligopeptidase B), PtrB | 0.0052 | 0.2275 | 0.5 |
Echinococcus granulosus | prolyl endopeptidase | 0.013 | 0.7278 | 0.7278 |
Leishmania major | prolyl oligopeptidase, putative,serine peptidase clan SC, family S9A, putative | 0.013 | 0.7278 | 1 |
Trichomonas vaginalis | cat eye syndrome critical region protein 2, cscr2, putative | 0.0043 | 0.1746 | 0.5 |
Trypanosoma brucei | serine peptidase, clan SC, family S9A-like protein | 0.0052 | 0.2275 | 0.3126 |
Schistosoma mansoni | prolyl oligopeptidase (S09 family) | 0.013 | 0.7278 | 0.7278 |
Trypanosoma cruzi | oligopeptidase B-like protein, putative | 0.0052 | 0.2275 | 0.3126 |
Trypanosoma cruzi | oligopeptidase b | 0.0052 | 0.2275 | 0.3126 |
Trypanosoma brucei | oligopeptidase b | 0.0052 | 0.2275 | 0.3126 |
Echinococcus multilocularis | gcn5proteinral control of amino acid synthesis | 0.0147 | 0.8405 | 0.8405 |
Trichomonas vaginalis | bromodomain-containing protein, putative | 0.0043 | 0.1746 | 0.5 |
Leishmania major | oligopeptidase B-like protein,serine peptidase, clan SC, family S9A-like protein | 0.0052 | 0.2275 | 0.3126 |
Echinococcus granulosus | histone acetyltransferase KAT2B | 0.0043 | 0.1746 | 0.1746 |
Loa Loa (eye worm) | hypothetical protein | 0.0153 | 0.8806 | 1 |
Mycobacterium leprae | PROBABLE PROTEASE II PTRBB (OLIGOPEPTIDASE B) | 0.0052 | 0.2275 | 0.5 |
Brugia malayi | prolyl oligopeptidase family protein | 0.013 | 0.7278 | 0.8264 |
Mycobacterium tuberculosis | Probable protease II PtrBa [first part] (oligopeptidase B) | 0.0116 | 0.6406 | 1 |
Leishmania major | oligopeptidase b | 0.0052 | 0.2275 | 0.3126 |
Mycobacterium tuberculosis | Probable peptidase | 0.0052 | 0.2275 | 0.3551 |
Schistosoma mansoni | hypothetical protein | 0.0172 | 1 | 1 |
Schistosoma mansoni | prolyl oligopeptidase (S09 family) | 0.013 | 0.7278 | 0.7278 |
Trypanosoma brucei | prolyl oligopeptidase, putative | 0.0052 | 0.2275 | 0.3126 |
Schistosoma mansoni | hypothetical protein | 0.0172 | 1 | 1 |
Brugia malayi | acetyltransferase, GNAT family protein | 0.0147 | 0.8405 | 0.9544 |
Mycobacterium tuberculosis | Probable protease II PtrBb [second part] (oligopeptidase B) | 0.0052 | 0.2275 | 0.3551 |
Trypanosoma brucei | prolyl endopeptidase | 0.013 | 0.7278 | 1 |
Echinococcus multilocularis | geminin | 0.0172 | 1 | 1 |
Schistosoma mansoni | gcn5proteinral control of amino-acid synthesis 5-like 2 gcnl2 | 0.0147 | 0.8405 | 0.8405 |
Brugia malayi | hypothetical protein | 0.0153 | 0.8806 | 1 |
Onchocerca volvulus | 0.0153 | 0.8806 | 1 | |
Entamoeba histolytica | acetyltransferase, GNAT family | 0.004 | 0.1515 | 0.5 |
Toxoplasma gondii | histone lysine acetyltransferase GCN5-B | 0.0043 | 0.1746 | 0.2399 |
Toxoplasma gondii | prolyl endopeptidase | 0.013 | 0.7278 | 1 |
Toxoplasma gondii | histone lysine acetyltransferase GCN5-A | 0.0043 | 0.1746 | 0.2399 |
Trypanosoma cruzi | oligopeptidase b | 0.0052 | 0.2275 | 0.3126 |
Plasmodium vivax | histone acetyltransferase GCN5, putative | 0.0043 | 0.1746 | 1 |
Echinococcus multilocularis | prolyl endopeptidase | 0.013 | 0.7278 | 0.7278 |
Loa Loa (eye worm) | acetyltransferase | 0.0147 | 0.8405 | 0.9544 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.